Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBITDA: 2020-2025

Historic EBITDA for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -$27.5 million.

  • Caribou Biosciences' EBITDA rose 18.11% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.8 million, marking a year-over-year decrease of 7.84%. This contributed to the annual value of -$148.9 million for FY2024, which is 48.11% down from last year.
  • Latest data reveals that Caribou Biosciences reported EBITDA of -$27.5 million as of Q3 2025, which was up 49.29% from -$54.2 million recorded in Q2 2025.
  • Caribou Biosciences' EBITDA's 5-year high stood at -$9.8 million during Q3 2023, with a 5-year trough of -$54.2 million in Q2 2025.
  • Over the past 3 years, Caribou Biosciences' median EBITDA value was -$33.6 million (recorded in 2024), while the average stood at -$33.7 million.
  • Per our database at Business Quant, Caribou Biosciences' EBITDA crashed by 534.63% in 2021 and then skyrocketed by 63.67% in 2023.
  • Over the past 5 years, Caribou Biosciences' EBITDA (Quarterly) stood at -$18.6 million in 2021, then crashed by 42.22% to -$26.5 million in 2022, then decreased by 26.53% to -$33.5 million in 2023, then fell by 7.55% to -$36.0 million in 2024, then increased by 18.11% to -$27.5 million in 2025.
  • Its last three reported values are -$27.5 million in Q3 2025, -$54.2 million for Q2 2025, and -$40.1 million during Q1 2025.